Malignant gliomas in adults.

By P. Wen, S. Kesari. New England Journal of Medicine, 2008

4,162 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e4ad7a62fce7a2af834424357693d7b613c0b52a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

In Pulmonary and Respiratory Medicine

Eric C. Holland

Citations in the corpus

Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “(including high-dose dexamethasone for tumor-related edema) provides a modest increase in survival from 3 to 4 months to no more than 6 months [1].”
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma (2010, background): “For instance, patients with glioblastoma, the most prevalent and most aggressive glioma variant, have a median survival of only 15 month”
Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma (2017, neutral): “GBMs are incurable tumors; despite aggressive treatment including surgical resection, chemotherapy and radiotherapy, the median overall survival remains only 12-18 months (Wen and Kesari, 2008).”
The brain tumor microenvironment (2011, background): “Defects in growth factor signaling pathways are a common molecular hallmark of malignant gliomas (Wen and Kesari, 2008).”
Metabolic Modulation of Glioblastoma with Dichloroacetate (2010, background): “GBMs are very vascular tumors with remarkablemolecular and genetic heterogeneity (1).”
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010, background): “Gliomas are the most common form of malignant primary brain tumors in adults, with an annual incidence of approximately four to five per 100,000 people.(1,2) The evaluation of treatment in high-grade gliomas currently relies either on the duration of patient survival or, more commonly in patients wi”
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. (2013, methodology): “Standard treatment for AO/AOA is surgical resection followed by radiotherapy (RT).(9) With treatment, survival times are much longer for AO/ AOA than for glioblastoma (GBM), a related cancer.”
MEF promotes stemness in the pathogenesis of gliomas (2012, neutral): “Despite the implementation of new therapeutic strategies, the median survival of patients with Glioblastoma multiforme (GBM), the most aggressive glioma variant, is only 14–16 months and these tumors remain rapidly and uniformly fatal (Wen and Kesari, 2008).”
CSF-1R inhibition alters macrophage polarization and blocks glioma progression (2013, methodology): “Human glioma–derived tumor sphere lines (TS1137 and TS573) were derived from consenting patients under Institutional Review Board (IRB)-approved protocols for the banking of excess tumor tissue during routine surgical resection (MSKCC IRB# 99-125A(2) and 06-107), as previously described61.”
Pathomic Fusion: An Integrated Framework for Fusing Histopathology and Genomic Features for Cancer Diagnosis and Prognosis (2019, background): “genomic assays is the standard-of-care for most cancers in modern clinical settings [1]–[4].”